In summary, we demonstrated that inhibition of the PI3K/AKT/mTOR and SRC/FAK pathways utilizing PKI-587 and dasatinib exhibits anti-tumor effects in MIBC with concomitant EGFR amplification and PTEN deletion, thus providing additional potential treatment options through a precision medicine approach. Here, PTK2 is linked to neoplasm.